Shin Poong Pharm. said on June 26 that it has signed a contract with Neopharm, a Uzbekistan pharmaceutical company, to supply its drug to prevent or reduce post surgical adhesion formation, called "Medicurtain."
According to the company, Shin Poong will exclusively supply Medicurtain to Uzbekistan, and the five-year contract is worth $5.67 million (about 6.6 billion won). Trademarks and patents are owned by Shin Poong.
Medicurtain, developed by Shin Poong with its own technology, is considered to be a unique product developed as a drug to prevent or reduce post surgical adhesion formation after hysteroscopic (gynecology), abdominal, spinal, thyroid and nasal/sinus surgeries.
The company also explained that it is a product that satisfies both medical staff and patients by minimizing side effects from post-operative adhesion, and has both film-type effects and liquid-type convenience.
Medicurtain won the Presidential Award at the Korea Patent Competition and acquired the European Union's CE certification and medical device quality management system certification "ISO 13485" for the first time in Korea.
It has also applied for patents (registered) in the U.S., Japan, Australia, Canada, China, and Europe and is expected to be a global blockbuster product.
"This time, we have set the stage for expansion to large markets such as Russia and Eurasian countries through the first large-scale contract with the Commonwealth of Independent States (CIS) country," a company official said.
